Can a New AI-Designed Drug Slow Aging?
A drug designed by artificial intelligence to treat a fatal lung disease has produced a serendipitous clinical signal, raising a far more ambitious question: can medicine intentionally alter the biological processes of aging?
Rentosertib, an experimental therapy developed by Insilico Medicine, was never conceived as a longevity drug. Its primary indication is idiopathic pulmonary fibrosis (IPF), a progressive disease where accumulating scar tissue in the lungs leads to respiratory failure. A recent analysis of patients treated with the asset, however, revealed a striking finding. Across six distinct proteomic models used to estimate biological age, patients receiving rentosertib demonstrated shifts toward younger predicted ages.
The finding is compelling, but it does not mean rentosertib is reversing human aging. The analysis included just 42 patients followed for 12 weeks and measured changes in blood proteins rather than lifespan, longevity, or the development of age-related disease.
Even with those limitations, the study brings together two rapidly advancing areas of medicine. AI is changing how researchers discover and design potential drugs, while scientists are developing new ways to measure and potentially influence the biology of aging.
From Generative AI to Human Trials
Traditional drug discovery faces two formidable bottlenecks: identifying a viable biological target implicated in a disease and then engineering a molecule that can safely and effectively act upon it. Insilico Medicine deployed its AI platform to systematically address both challenges. The system pinpointed TRAF2- and NCK-interacting kinase, or TNIK, as a high-potential therapeutic target for IPF. Subsequently, its generative chemistry algorithms designed novel molecules capable of inhibiting this protein, a process that ultimately yielded rentosertib.
TNIK is a kinase deeply involved in biological pathways linked to inflammation and fibrosis. The velocity of the program was notable; researchers progressed from target identification to selecting a preclinical candidate in approximately 18 months, highlighting the strategic advantage AI offers in navigating the vast chemical space to find promising candidates.
Rentosertib has since advanced into human trials, where a randomized Phase IIa study produced encouraging results. Patients receiving the highest dose experienced an average 98.4 mL increase in forced vital capacity (FVC), a key measure of lung function, which contrasted sharply with a 20.3 mL decline observed in the placebo arm.
The trial, however, was designed to study pulmonary fibrosis. The connection to aging emerged later.
Did Rentosertib Actually Slow Aging?
To probe deeper, researchers analyzed over 2,800 proteins in blood samples from 42 trial participants, applying six different “proteomic aging clocks” to the dataset. These computational models estimate biological age by identifying molecular patterns in the proteome associated with chronological aging. Unlike calendar age, biological age aims to capture the functional status of an individual's body, reflecting underlying differences in inflammation, organ function, and disease risk.
All six models registered reductions in predicted biological age for patients treated with rentosertib compared to placebo, with some estimates indicating a divergence of several years. While this could be interpreted as the AI-designed drug making patients biologically younger, the evidence is far more complex. A significant confounding variable is that IPF itself profoundly impacts inflammation and the profile of proteins circulating in the blood. If rentosertib effectively mitigates these disease-related processes, the aging clocks could merely be interpreting the normalization of disease pathology as a reversal of biological age, even if the fundamental aging process remains untouched.
Furthermore, the small, short-duration study provides no data on whether these changes would occur in healthy adults, persist with longer-term treatment, or translate into a tangible reduction in age-related morbidity or mortality.
AI's Bigger Test
Rentosertib is now advancing into a Phase III trial involving 320 patients who will be followed for 52 weeks. The trial remains focused on determining whether the drug can effectively treat IPF, but its larger scale may also offer more insight into whether the biological-age changes persist.
For now, rentosertib remains an experimental treatment for lung disease, not an anti-aging drug. Still, its development points to a broader possibility for AI-driven medicine.
Artificial intelligence can analyze vast biological datasets, identify previously overlooked targets and generate promising drug candidates. Clinical trials must still determine whether those candidates are safe and improve patients’ lives. But as more AI-designed drugs enter human testing, researchers may encounter effects that were never part of the original therapeutic goal.
Rentosertib was developed to determine whether targeting TNIK could help treat pulmonary fibrosis. Its clinical development has now raised a question that extends beyond IPF. As AI expands the range of biological targets and molecules researchers can investigate, what other unexpected effects might emerge along the way?
Read more about the impact of federal research funding cuts on the future of medicine and learn about the most anticipated drug launches of 2025.
Further Reading:
If you liked this article:
Share this article with your network on LinkedIn with your thoughts or perspectives. Make sure to tag us @HealthcareInsights to join the conversation.
Subscribe to our free newsletter, HealthcareIn Quicktakes. You'll never miss an article, and will get access to exclusive reports.
Check out our library of articles and reports on biotech, healthcare, policy, and business.
Who We Are: At Healthcare Insights, we're covering the transformation of healthcare and bringing our readers the most pertinent takes on key issues in medicine, biotech, healthcare policy, and business. Our Spotlight Series ✦ features thoughts from the most influential figures in healthcare, including Nobel Prize-winning scientists shaping tomorrow's treatments and business leaders bringing new therapies to market. We strive to publish coverage that is authentic, impartial, and independent of any financial or political motive. For more information regarding our editorial standards, read our statement. If you'd like to contact the Editor, use this form to get in touch.
If you'd like to stay in the loop, make sure to subscribe to our free newsletter, HealthcareIn Quicktakes, and follow us @healthcareinsights across our social channels, including LinkedIn.
©️ Copyright 2026 Healthcare Insights
All Rights Reserved
